Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2004
  • Online publication date: December 2009

8 - Treatment for colorectal cancer: impact on health-related quality of life

Summary

Introduction

Colorectal cancer (CRC) is the second leading cause of cancer death in the US each year. It is estimated that in 2002 there were 148 300 new cases and 56 600 deaths from CRC. Direct evidence from randomized trials and indirect evidence from case-control and cohort studies– suggest that screening affects 5-year survival. Specifically, screening can identify pre-cancerous lesions and prevent development of CRC or identify CRC in earlier stages (I and II) when it can be treated more effectively. The relative 5-year survival rates for early-stage disease (I and II) and advanced disease have been estimated at 65%–90% and 9%, respectively. Because most patients diagnosed with CRC have not undergone screening, most CRCs are diagnosed after local or regional spread, and nearly half of all patients so diagnosed will die from it.

Treatment for CRC is based on the stage and location of disease and includes surgery, chemotherapy, and/or radiation therapy. These modalities may be associated with substantial toxicity, including hair loss, profound nausea and vomiting, and fecal incontinence. Furthermore, therapy for CRC may result in the formation of a permanent or temporary stoma. All of these treatments may have side effects that have an important effect on health-related quality of life (HRQOL).

Treatment for colon cancer includes surgical resection for stage I and II disease, and surgery plus chemotherapy for stage III and selected patients with stage IV disease. Palliative care is provided to patients with unresectable disease.

REFERENCES
National Cancer Institute. Colorectal Screening. http://www.cancer.gov/cancerinfo/pdq/screening/colorectal/healthprofessional. Last accessed September 11, 2004
Mandel, J. S., Bond, J. H., Church, T. R.et al. (1993). Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control StudyNew England Journal of Medicine 328:1365–71
Selby, J. V., Friedman, G. D., Quesenberry, C. P. Jr.et al. (1992). A case-control study of screening sigmoidoscopy and mortality from colorectal cancerNew England Journal of Medicine 326:653–7
Newcomb, P. A., Norfleet, R. G., Storer, B. E.et al. (1992). Screening sigmoidoscopy and colorectal cancer mortalityJournal of the National Cancer Institute 84:1572–5
Muller, A. D., Sonnenberg, A. (1995). Protection by endoscopy against death from colorectal cancerArchives of Internal Medicine 155:1741–8
National Cancer Institute. Colon cancer treatment. http://www.cancer.gov/cancerinfo/pdq/treatment/colon. Last accessed September 11, 2004
Ries, L. A. G., Eisner, M. P., Kosary, C. L. et al. (eds). (2002). SEER Cancer Statistics Review, 1973–1999. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1973_1999. Accessed September 11, 2004
Aaronson, N. K., Ahmedzai, S., Bergman, B.et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncologyJournal of the National Cancer Institute 85:365–76
Kaasa, S., Mastekaasa, A., Stokke, I.et al. (1988). Validation of a quality of life questionnaire for use in clinical trials for treatment of patients with inoperable lung cancerEuropean Journal of Cancer and Clinical Oncology 24:691–701
Glimelius, B., Hoffman, K., Olafsdottir, M.et al. (1989). Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimensEuropean Journal of Cancer and Clinical Oncology 25:829–35
Adang, E. M., Engel, G. L., Konsten, J.et al. (1993). Quality of life after dynamic graciloplasty for fecal incontinence: first resultsThoracic Surgery 8:122–4
Renner, K., Rosen, H. R., Novi, G.et al. (1999). Quality of life after surgery for rectal cancer: do we still need a permanent colostomy?Diseases of the Colon and Rectum 42:1160–7
Björvell, H., Hylander, B. (1989). Functional status and personality in patients on chronic dialysisJournal of Internal Medicine 226:319–24
Forsberg, C., Bjorvell, H., Cedermark, B. (1996). Well-being and its relation to coping ability in patients with colo-rectal and gastric cancer before and after surgeryScandinavian Journal of Caring Science 10:35–44
Schipper, H., Clinch, J., McMurray, A.et al. (1984). Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validationJournal of Clinical Oncology 2:472–83
Morrow, G. R., Lindke, J., Black, P. (1992). Measurement of quality of life in patients: psychometric analyses of the Functional Living Index-Cancer (FLIC)Quality of Life Research 1:287–96
Haes, J. C. J. M., Oostrom, M. A., Welvaart, K. (1986). The effect of radical and conserving surgery on the quality of life of early breast cancer patients.European Journal of Surgical Oncology 12:337–42
de Haes, J. C. J. M., Raatgever, J. W., van der Burg, M. E. L. et al. (1987). Evaluation of the quality of life of patients with advanced ovarian cancer treated with combination chemotherapy. In The Quality of Life of Cancer Patients, ed. N. K. Aaronson, J. Beckman, pp. 215–26. New York: Raven Press
Haes, J. C. J. M., Knippenberg, F. C. E., Neijt, J. P. (1990). Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom ChecklistBritish Journal of Cancer 62:1034–38
Haes, J. C. J. M., Olschewski, M. (1998). Quality of life assessment in a cross-cultural context: use of the Rotterdam Symptom Checklist in a multinational randomised trial comparing CMF and Zoladex (Goserlin) treatment in early breast cancerAnnals of Oncology 9:745–50
Spitzer, W. O., Dobson, A. J., Hall, J.et al. (1983). Measuring the quality of life of cancer patients. A concise QL- Index for use by physiciansJournal of Chronic Disease 34:585–97
EuroQoL Group (1990). EuroQoL — a new facility for the measurement of health-related quality of lifeHealth Policy 16:199–208
Kind, P. (1996). The EuroQoL instrument: an index of health-related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edn), ed. B. Spilker, pp. 191–201. Philadelphia, PA: Lippincott-Raven
Zigmund, A. S., Snaith, R. P. (1983). The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica 67:361–70
Hunt, S. M., McEwen, J., McKenna, S. P. (1986). Measuring Health Status. London: Croom Helm
Hunt, S. M., McKenna, S. P. (1991). The Nottingham Health Profile User's Manual. Manchester: Galen Research and Consultancy
McEwen, J., McKenna, S. P. (1996). Nottingham Health Profile. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition), ed. B. Spilker, pp. 281–86. Philadelphia, PA: Lippincott-Raven
Lorr, M., McNair, D. M. (1982). Profile of Mood States: Bi-polar Form. San Diego: Educational and Industrial Testing Service
Shacham, S. (1983). A shortened version of the Profile of Mood StatesJournal of Personality Assessment 47:305–6
Bergner, M., Bobbitt, R. A., Carter, W. B.et al. (1981). The Sickness Impact Profile: development and final revision of a health status measureMedical Care 19:787–805
Damiano, A. M. (1996). The Sickness Impact Profile. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition), ed. B. Spilker, pp. 347–54. Philadelphia, PA: Lippincott-Raven
Erickson, this volume, Chapter 3
Fayers, P., Aaronson, N., Bjordal, K. et al., on behalf of the EORTC Quality of Life Group. (2001). EORTC QLQ-C30 Scoring Manual (3rd Edition). Brussels: EORTC
Fayers, P., Weeden, S., Curran, D. (1998). EORTC QLQ-C30 Reference Values. Brussels: EORTC Study Group on Quality of Life
Sprangers, M. A., Cull, A., Bjordal, K.et al., for the EORTC Study Group on Quality of Life (1993). The European Organization for Research and Treatment of Cancer approach to quality of life assessment: Guidelines for developing modulesQuality of Life Research 2:287–95
Sprangers, M. A. G. (1999). Quality-of-life assessment in colorectal cancer patients: evaluation of cancer therapiesSeminars in Oncology 26:691–6
Aaronson, N. K., Cull, A. M., Kaasa, S. et al. (1996). The European Organization for Research and Treatment of Cancer (EORTC) Modular Approach to Quality of Life Assessment in Oncology: An update. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition), ed. B. Spilker, pp. 179–89. Philadelphia, PA: Lippincott-Raven
Sprangers, M. A. G., te Velde, A.,Aaronson, N. K. on behalf of the European Organization for Research and Treatment of Cancer Study Group on Quality of Life (1999). The construction of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38)European Journal of Cancer 35:238–47
Sailer, M., Debus, E. S., Fuchs, K.-H. (2000). How useful is the EORTC QLQ-CR38 in the pre- and post-operative evaluation of patients with rectal cancer?Quality of Life Research Newsletter 25:13–14
Cella, D. F., Tulsky, D. S., Gray, G.et al. (1993). The Functional Assessment of Cancer Therapy scale: development and validation of the general measureJournal of Clinical Oncology 11:570–9
Cella, D. (1997). FACIT Manual. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Version 4. Evanston, IL: Center on Outcomes, Research and Education (CORE)
Ward, W. L., Hahn, E. A., Mo, F.et al. (1999). Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrumentQuality of Life Research 8:181–95
Courneya, K. S., Friedenreich, C. M. (1997). Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivorsJournal of Alternative and Complementary Medicine 3:215–26
Allal, A. S., Bieri, S., Peloni, A.et al. (2002). Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomesBritish Journal of Cancer 82:1131–7
Cronbach, L. J. (1951). Coefficient alpha and the internal structure of testsPsychometrika 16:297–334
Borras, J. M., Sanchez-Hernandez, A., Navarro, M.et al. (2001). Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trialBritish Medical Journal 322:1–5
Bernhard, J., Hürny, C., Maibach, R., Herrmann, R.et al., for the Swiss Group for Clinical Cancer Research (SAKK). (1999). Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapyAnnals of Oncology 10:775–82
Ulander, K., Jeppsson, B., Grahn, G. (1997). Quality of life and independence in activities of daily living preoperatively and at follow-up in patients with colorectal cancerSupportive Care in Cancer 5:402–9
Whynes, D. K., Neilson, A. R. (1997). Symptoms before and after surgery for colorectal cancerQuality of Life Research 6:61–6
Barsevick, A. M., Pasacreta, J., Orsi, A. (1995). Psychological distress and functional dependence in colorectal cancer patientsCancer Practice 3:105–10
Padilla, G. V., Grant, M. M., Lipsett, J.et al. (1992). Health quality of life and colorectal cancerCancer 70:1450–6
Scieszka, M., Zielinski, M., Machalski, M.et al. (2000). Quality of life in cancer patients treated by chemotherapyNeoplasma 47:396–9
Anthony, T., Jones, C., Antoine, J.et al. (2001). The effect of treatment for colorectal cancer on long-term health-related quality of lifeAnnals of Surgical Oncology 8:44–9
McHorney, C. A., Ware, J. E. Jr., Raczek, A. E. (1993). The MOS 36-item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructsMedical Care 31:247–63
Langius, A., Björvell, H., Antonovsky, A. (1992). The Sense of Coherence concept and its relation to personality traits in Swedish samplesScandinavian Journal of Caring Science 6:165–71
Antonovsky, A. (1987). Unraveling the Mystery of Health: How People Manage Stress and Stay Well. San Francisco, CA: Jossey-Bass Publishers
Garufi, C., Brienza, S., Pugliese, P.et al. (2000). Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patientsAnticancer Drugs 11:495–501
Garufi, C., Dogliotti, L., D'Attino, R. M.et al. (2001). Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I studyCancer 91:712–20
Hauns, B., Häring, B., Köhler, S.et al. (2001). Phase II study of combined 5 fluorouracil/Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancerPhytotherapy Research 15:34–8
Henry, B., Becouarn, Y., Aussage, P. (1999). Clinical benefits of stabilization with second line chemotherapy in patients with metastatic colorectal cancerOncology Hematology 32:145–54
Fordy, C., Glover, C., Davies, M. M.et al. (1998). Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastasesBritish Journal of Cancer 78:1058–60
Cunningham, D., Zalcberg, J. R., Rath, U.et al. (1996). Final results of a randomised trial comparing ‘Tomudex’ (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. “Tomudex” Colorectal Cancer Study GroupAnnals of Oncology 7:961–5
Cunningham, D., Glimelius, B. on behalf of the V301 Study Group. (1999). A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study GroupSeminars in Oncology 26:6–12
Gramont, A., Figer, A., Seymour, M.et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerJournal of Clinical Oncology 18:2938–47
Douillard, J. Y., Cunningham, D., Roth, A. D.et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialLancet 355:1041–7
Hill, M., Norman, A., Cunningham, D.et al. (1995). Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancerJournal of Clinical Oncology 13:2317–23
Ross, P., Norman, A., Cunningham, D.et al. (1997). A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancerAnnals of Oncology 8:995–1001
Rougier, P., Cutsem, E., Bajetta, E.et al. (1998). Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerLancet 352:1407–12
Saltz, L. B., Cox, J. V., Blanke, C.et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupNew England Journal of Medicine 343:905–14
Cutsem, E., Blijham, G. H. on behalf of the V302 Study Group. (1999). Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracilSeminars in Oncology 26:13–20
Norum, J., Vonen, B., Olsen, J. A.et al. (1997). Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost-effectiveness analysisAnnals of Oncology 8:65–70
Allen-Mersh, T. G., Earlam, S., Fordy, C.et al. (1994). Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastasesLancet 344:1255–60
Allen-Mersh, T. G., Glover, C., Fordy, C.et al. (2000). Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastasesEuropean Journal of Surgical Oncology 26:468–73
Cocconi, G., Cunningham, D., Cutsem, E.et al. (1998). Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study GroupJournal of Clinical Oncology 16:2943–52
Earlam, S., Glover, C., Davies, M.et al. (1997). Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patientsJournal of Clinical Oncology 15:2022–9
Seymour, M. T., Slevin, M. L., Kerr, D. J.et al. (1996). Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research CouncilJournal of Clinical Oncology 14:2280–8
Sobrero, A., Zaniboni, A., Frassineti, G. L.et al. (2000). Schedule specific biochemical modulations of 5-fluorouracil in advanced colorectal cancer: A randomized study. GISCAD, IOR and collaborating centersAnnals of Oncology 11:1413–20
Caudry, M., Bonnel, C., Floquet, A.et al. (1995). A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinomaAmerican Journal of Clinical Oncology 18:118–25
Loprinizi, C. L., Juross, S. A., O'Fallon, J. R.et al. (1994). Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancerJournal of Clinical Oncology 12:1121–5
Smyth, J. F., Hardcastle, J. D., Denton, G.et al. (1995). Two phase III trials of tauromustine (TCNU) in advanced colorectal cancerAnnals of Oncology 6:948–9
Laufman, L. R., Bukowski, R. M., Collier, M. A.et al. (1993). A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancerJournal of Clinical Oncology 11:1888–93
Scheithauer, W., Rosen, H., Kornek, G.-V.et al. (1993). Randomized comparison of combination 4 chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancerBritish Medical Journal 306:752–5
Sullivan, B. A., McKinnis, R., Laufman, L. R. (1995). Quality of life in patients with metastatic colorectal cancer receiving chemotherapy: a randomized, double-blind trial comparing 5-FU versus 5-FU with leucovorinPharmacotherapy 15:600–7
Glimelius, B., Hoffman, K., Graf, W.et al. (1994). Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancerCancer 73:556–62
Leichman, C. G., Fleming, T. R., Muggia, F. M.et al. (1995). Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group studyJournal of Clinical Oncology 13:1303–11
Moinpour, C. M., Triplett, J. S., McKnight, B.et al. (2000). Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trialPsycho-Oncology 9:340–54
Moinpour, C. M., Savage, M., Hayden, K. A. et al. (1995). Quality of Life Assessment in Cancer Clinical Trials. In Quality of Life in Behavioral Medicine Research, ed. J. E. Dimsdale, A. Braun, pp. 79–95. Hillsdale, NJ: Lawrence Erlbaum Associates
Feeny, D., Furlong, W., Boyle, M.et al. (1995). Multi-attribute health status classification systems: Health Utilities IndexPharmacoeconomics 7:490–502
Tobin, E. (2001). Report on Focus Group Research. Conducted for NCI's COMWG with cancer patients and survivors by Cancer Care Strategies. September, 2001. Completed under contract to the National Cancer Institute by E. Tobin
Zebrack, Cella, this volume, Chapter 11
Bernhard, J., Cella, D. F., Coates, A. S.et al. (1998). Missing quality of life data in cancer clinical trials: serious problems and challengesStatistics in Medicine 17:517–32
Hogan, J. W., Laird, N. M. (1997). Mixture models for the joint distribution of repeated measures and event timesStatistics in Medicine 16:239–57
Fairclough, this volume, Chapter 17
Sprangers, M. A. G., Taal, B. G., Aaronson, N. K.et al. (1995). Quality of life in colorectal cancer. Stoma vs. nonstoma patientsDiseases of the Colon and Rectum 38:361–9
Camilleri-Brennan, J., Steele, R. J. C. (1998). Quality of life after treatment for rectal cancerBritish Journal of Surgery 85:1036–43
Wils, J., Sahmoud, T., Sobrero, A.et al. (1998). Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCGTumori 84:335–47
Sobrero, A., Belvedere, O., Ramello, M.et al. (2001). Endpoints of medical treatment of colorectal cancerTumori 87(Suppl. 1):S63–4
Allen, M., Cunningham, D., Schmitt, C. (1998). The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studiesAnti-Cancer Drugs 9:783–90
Cull, A., Groenvold, M., on behalf of the EORTC Quality of Life Study Group. (1998). EORTC Quality of Life Study Group Translation Procedure. ISBN: 2-930064-15–3. Brussels: EORTC
Beck, A. T., Steer, R. A. (1987). Beck Depression Inventory (BDI) Manual. San Antonio: Harcourt Brace Jovanovich
Benoliel, J. Q., McCorkle, R., Young, K. (1983). The development of a social dependency scaleResearch in Nursing and Health 3:3–10
McCorkle, R. M., Benoliel, J. Q., Donaldson, G.et al. (1989). A randomized clinical trial of home nursing care for lung cancer patientsCancer 57:358–64
Priestman, T., Baum, M. (1976). Evaluation of quality of life in patients receiving treatment for advanced breast cancerLancet 24:899–900
Coates, A., Gebski, V., Bishop, J. F.et al. (1987). Improving the quality of life during chemotherapy for advanced breast cancerNew England Journal of Medicine 317:1633–7
Ware, J. E. Jr., Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMedical Care 30:473–83
McHorney, C. A., Ware, J. E. Jr., Lu, J. F. R., Sherbourne, C. D. (1994). The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groupsMedical Care 32:40–66
Ware, Jr., J. E., Snow, K. K., Kosinski, M. et al. (1993). SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute